Chronic graft-versus-host disease (chronic GVHD) is a condition where donated immune cells from a stem cell or bone marrow transplant attack the recipient’s body, treating healthy tissues as foreign invaders. It affects roughly 30 to 70% of people who receive a transplant from another person, making it one of the most common and serious long-term complications of this life-saving procedure. Unlike its acute counterpart, which typically strikes in the first few months, chronic GVHD can develop months or even years after transplant and often resembles autoimmune diseases like scleroderma or Sjögren’s disease.
How Chronic GVHD Develops
After an allogeneic transplant (one using a donor’s cells), the new immune system is supposed to rebuild itself and protect you from infection and disease relapse. But sometimes the donated immune cells, particularly certain types of white blood cells called T cells and B cells, begin recognizing your tissues as threats. The process starts when tissue damage from the transplant itself releases signals that activate the donor’s immune cells, putting them on high alert.
Those activated T cells then drive a cascade of inflammation. They differentiate into aggressive subtypes that can damage the skin, liver, lungs, gastrointestinal tract, and other organs. Over time, donor T cells and B cells begin working together in a particularly damaging way: B cells start producing antibodies directed against your own tissues. Some of these antibodies target proteins unique to your body, while others attack proteins shared by both you and the donor, essentially creating an autoimmune-like state. This cooperation between T cells and B cells is a hallmark of chronic GVHD and helps explain why the disease can affect so many different parts of the body simultaneously.
Which Organs Are Affected
Chronic GVHD can show up in a single organ or hit multiple systems at once. The skin is the most commonly involved, with changes ranging from flat, discolored patches (similar to lichen planus) to thickened, tight skin that resembles scleroderma. This tightening can restrict joint movement if it develops over the hands, arms, or legs.
The mouth and eyes are frequently affected too. Dry mouth, painful sores, and difficulty eating are common oral symptoms. The eyes often develop severe dryness, sometimes called “dry eye syndrome,” where the body stops producing enough tears to keep the eye surface healthy. In more serious cases, the lungs can develop a condition called bronchiolitis obliterans, where the small airways become scarred and narrowed, making it progressively harder to breathe. The gastrointestinal tract may develop ulcerations and scarring, while the liver can show elevated bilirubin levels, signaling damage to the bile ducts.
Risk Factors for Developing Chronic GVHD
Not everyone who receives a donor transplant will develop chronic GVHD, and several factors influence the odds. The most consistently identified risk factors include:
- Prior acute GVHD: Having the acute form of the disease is one of the strongest predictors of later developing the chronic form.
- Donor mismatch: Using an unrelated or HLA-mismatched donor raises risk substantially. Transplants from HLA-mismatched unrelated donors carry about 76% higher risk compared to matched related donors.
- Donor-recipient sex mismatch: Receiving cells from a female donor when the recipient is male increases risk by roughly 38%.
- Graft source: Transplants using mobilized blood stem cells (collected from the bloodstream rather than directly from bone marrow) carry about 74% higher risk.
- Older age: Both older recipient age and older donor age independently raise the likelihood, with risk climbing about 13% per decade of recipient age and 9% per decade of donor age.
How Chronic GVHD Is Diagnosed and Staged
Diagnosis follows guidelines established by the National Institutes of Health. To confirm chronic GVHD, doctors look for at least one “diagnostic” sign, meaning a feature so characteristic it can only be explained by the disease. Alternatively, they may identify a “distinctive” feature (one that’s suggestive but not definitive) and confirm it through biopsy, lung function testing, a Schirmer’s test for tear production, or evaluation by a specialist like an ophthalmologist.
Once diagnosed, chronic GVHD is classified into three severity levels based on how many organs are involved and how badly each one is affected. Mild disease means only one or two organs are involved with minor symptoms and no lung involvement. Moderate disease involves three or more organs with minor symptoms, or at least one organ with more significant damage, or early lung involvement. Severe disease means at least one organ has major damage, or the lungs are substantially affected based on breathing tests. This staging directly guides treatment decisions.
First-Line Treatment
Corticosteroids remain the standard starting treatment for chronic GVHD. Most centers use prednisone at a dose based on body weight, typically combined with an immune-suppressing drug like cyclosporine or tacrolimus. The combination of a corticosteroid with cyclosporine, sometimes given on alternating days, may be more effective and cause fewer side effects than corticosteroids alone.
The challenge with corticosteroids is that long-term use brings significant side effects: bone thinning, high blood sugar, weight gain, muscle weakness, and increased infection risk. Many patients either don’t respond adequately to steroids or can’t tolerate them long enough, which is considered steroid-refractory disease. These patients need second-line options.
Second-Line and Newer Therapies
Several FDA-approved therapies now exist for chronic GVHD that hasn’t responded to initial treatment. Two of these, ibrutinib and ruxolitinib, are approved after at least one prior line of therapy has failed. Ibrutinib works by blocking signaling pathways in both B cells and T cells, addressing the two-pronged immune attack at the core of the disease. Ruxolitinib targets a different set of signaling molecules that relay messages from multiple inflammatory signals, broadly dampening the immune overreaction.
For patients who have tried two or more prior treatments without success, belumosudil and axatilimab are additional options. Belumosudil is particularly notable because it addresses fibrosis, the tissue scarring that drives many of the most debilitating symptoms of chronic GVHD, like skin tightening and lung damage. It also helps restore the balance between aggressive and regulatory immune cells. The availability of these targeted therapies has meaningfully expanded options for patients who previously had few choices beyond cycling through various immune suppressants.
Supportive Care and Daily Management
Because chronic GVHD can affect so many body systems, day-to-day management goes well beyond taking medication. For dry eyes, frequent use of artificial lubricant tears is a front-line measure. In more severe cases, doctors may plug or surgically close the tear ducts to keep whatever moisture the eyes produce from draining away too quickly. Specialized moisture-chamber eyewear can also help protect the eyes throughout the day.
Skin involvement requires careful, ongoing monitoring. A thorough skin exam at every clinic visit, including looking at, touching, and pinching the skin to assess texture and flexibility, is standard practice. When sclerotic (hardening) skin changes start limiting joint mobility, physical therapy becomes essential. Range of motion should be assessed at every visit, with formal physiotherapy evaluations recommended every three months until the tightening resolves. Consistent stretching and movement can prevent permanent contractures that would otherwise limit daily function.
Long-Term Outlook
Chronic GVHD is a serious condition, but many patients live with it for years while maintaining a reasonable quality of life. In a large analysis from the Chronic GVHD Consortium, the cumulative rate of death from causes other than cancer relapse was 7% at one year, 15% at three years, and 22% at five years after diagnosis. Cancer relapse itself accounted for about 25% of all deaths in these patients.
Among those who died from non-relapse causes, chronic GVHD itself was the most common identified reason, responsible for roughly 38% of those deaths, typically through organ failure or infection. Infection alone accounted for another 17%, and respiratory failure for 10%. These numbers underscore why ongoing monitoring, infection prevention, and prompt treatment adjustments matter so much. The disease is unpredictable: some people experience a single flare that resolves, while others deal with a chronic, fluctuating course requiring years of active management.